Gilead Sciences, Inc. $GILD Shares Bought by Dynamic Advisor Solutions LLC

Dynamic Advisor Solutions LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,991 shares of the biopharmaceutical company’s stock after acquiring an additional 6,569 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Gilead Sciences were worth $7,832,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Paulson Wealth Management Inc. increased its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the period. Essex Financial Services Inc. raised its holdings in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. boosted its position in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the period. Alpha Cubed Investments LLC grew its holdings in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares in the last quarter. Finally, Personal CFO Solutions LLC grew its holdings in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on GILD. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Wall Street Zen lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Rothschild & Co Redburn dropped their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.80 billion, above the approximately $7.40 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by double-digit HIV growth and continued momentum in Trodelvy. Gilead Q2 Earnings Beat on HIV and Trodelvy Growth
• Positive Sentiment: Management raised its HIV growth outlook to 9%-10% and lifted its 2026 base-business sales outlook to approximately $29.8 billion-$30.1 billion. Yeztugo, Gilead’s HIV PrEP treatment, generated roughly $1 billion in sales as uptake accelerated. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Needham reaffirmed its Buy rating with a $170 price target, while Cantor Fitzgerald maintained Overweight and a $155 target, indicating potential upside if HIV and oncology growth continues.
• Positive Sentiment: Gilead declared its quarterly dividend of $0.82 per share, supporting the stock’s income appeal. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s full-year EPS outlook improved relative to consensus, but revenue guidance of $30.1 billion-$30.4 billion remained slightly below analysts’ $30.5 billion estimate, reflecting acquisition and research spending.
• Negative Sentiment: The company posted a $6.75-per-share quarterly loss versus $2.01 of earnings a year earlier. Acquisition-related charges and research-and-development costs overshadowed the operating improvement and raised concerns about deeper 2026 losses. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and highlighting pressure from a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies, creating potential reputational and access-related risks in global markets. RBC maintained a Sector Perform rating with a $123 target, below the current valuation.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction is a limited signal because it was scheduled in advance, but it may add to investor caution.

Gilead Sciences Trading Down 2.6%

NASDAQ:GILD opened at $131.76 on Thursday. The stock has a fifty day simple moving average of $129.54 and a 200 day simple moving average of $136.18. The firm has a market capitalization of $163.59 billion, a price-to-earnings ratio of -49.35 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 1.86% and a negative net margin of 10.64%.The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,000 shares of company stock valued at $10,641,790 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.